Life Sciences

Thriving in a converging environment: learn how KPMG can help pharmaceutical, medical device and diagnostic companies turn disruption into opportunity.

Ash Shehata

‹

›

Email me

Ash Shehata

Principal, National Sector Leader for HCLS, KPMG US

+1 513-763-2428

Healthcare Reimagined

Featured client stories

Healthcare Life Sciences

Analyst Recognition

KPMG is a leader in The Forrester New Wave^TM in Healthcare RPA

Featured thought leadership

Research & Development Performance

How to spot leaders vs. laggards
ESG reporting – a new opportunity for CAOs

How Chief Accounting Officers can lean into the challenge to enhance their strategic roles
Managing risk and compliance in your SAP S/4HANA journey

Life sciences companies face unique governance, risks and compliance challenges when implementing SAP S/4HANA technology.
American Rescue Plan Act of 2021: Healthcare Related Provisions

The American Rescue Plan Act of 2021 expands healthcare coverage and provides pandemic funding
2021 Healthcare and Life Sciences Investment Outlook

Provides insights on how the political and regulatory environment, and market factors may impact investment decisions.
Revised Safe Harbor Protections for Prescription Drug Rebates

HHS final rule requires pharmacy benefit managers to pass along prescription drug rebates to patients at the point of sale
Most Favored Nation Drug Pricing Model final rule

On November 20, 2020, the Centers for Medicare and Medicaid Services announced the Most Favored Nation Drug Pricing Model
Generics 2030: Three strategies to curb the downward spiral

By 2030, generics manufacturers will need to shift from the status quo and explore one of three avenues for change.
Health Plan Transparency in Coverage Final Rule

HHS, Department of Labor, and Treasury finalized price transparency requirements for health plans set to take effect beginning in 2022
FDA final rule and guidance on importation of prescription drugs

FDA finalized a rule and guidance allowing states to submit prescription drug importation proposals and manufacturers to re-label drugs for importation
Executive order on ‘Most-Favored-Nation’ drug pricing

An Executive Order directs HHS rulemaking for “most favored nations” pricing for Medicare Part B and D drugs
COVID-19: Telemedicine and tax

As telemedicine accelerates, the need for greater tax clarity and updated guidance relating to virtual healthcare is evident.
Executive orders on prescription drug costs

Four Executive Orders (EO) described as action to deliver lower prescription drug prices to American Patients.
The clinical trial conundrum

Failing to resume clinical trials could present as many risks to certain patients as COVID-19
Re-launching elective procedures

An opportunity for medical device companies to shape their future customer base
KPMG Digital Lighthouse: Powering Life Sciences with advanced analytics

The Life Sciences Industry is moving towards a dramatically different future based on a number of market drivers.
Diagnostics: Ramp-up of testing for COVID-19 & beyond

Private labs seeking to restructure or build to deploy COVID-19 testing operations can benefit from KPMG’s rapid start-up approach
Restarting America – Practical Guide for Employers

For businesses making decisions about when and how to reopen their businesses, here is a practical guide to key considerations.
Paycheck Protection Program and Health Care Enhancement Act

Implications for Healthcare providers
Part D senior savings model for insulin coverage

CMS just announced alternative Part D options that lower seniors’ cost-sharing for insulin, according to the attached issue brief.
Accelerated/advance payment for medicare providers and suppliers

To learn more about enhancements to CMS’s Accelerated & Advance Payment Program to help providers & suppliers during COVID.
Coronavirus Aid, Relief, and Economic Security (CARES) Act

Economic support and stimulus bill
2020 healthcare and life sciences investment outlook

Analysis of the 2020 KPMG Healthcare and Life Sciences Investment Outlook survey sheds light on how the investment landscape will be impacted by influential disruptors, evolving market trends, and policy/regulatory developments.
The Race to EU MDR Compliance Continues

Despite progress, companies are still facing many questions
Quality 2030

Forward-thinking Life Sciences CXOs will transform Quality from a cost center to a value creator
Medical device regulatory affairs operational transformation

Key insights and opportunities to unlock additional value by streamlining Regulatory Affairs operational activities
An open target

Despite progress in corporate cybersecurity, life sciences operational technology is still vulnerable to increasingly sophisticated threats.
Global lessons in building a continuous improvement culture in healthcare

Building a culture of excellence in healthcare
Embracing transparency

Instead of viewing calls for transparency as a burden, pharmaceutical companies can take steps to turn pricing reform to their advantage.
Prescription drug rebates

Proposed safe harbor changes open for comment
Part D Payment Modernization Model

Consider applying for the voluntary initiative
Driving value from genomics in Life Sciences

Rising to the data challenge
Opportunities in an evolving market

2019 Health Care & Life Sciences Investment Outlook
R&D 2030

Reinvent innovation and become an R&D front-runner by 2030
Digital transformation in regulatory affairs

Unlocking value for life sciences organizations
Pharmaceuticals industry exec summary - Harvey Nash/KPMG CIO survey 2018

This CIO Survey is the largest IT leadership study in the world, and summarizes what we learned about the transformational CIO.
The race to EU MDR compliance

KPMG/RAPS survey illustrates the ground medical device companies still have to cover
Insider threat in life sciences

2018 Program benchmark report
Digital health and disruption in diabetes

Identifying opportunities for life sciences manufacturers.
Future of finance: Finance disrupted

Innovation in the life sciences finance function
The disruption challenge

As new entrants and cross-sector models abound, which direction should healthcare organizations turn?
Demystifying blockchain for life sciences

Blockchain could be a key to interoperability and privacy
Revenue for the life sciences industry

New standard. New challenges.
2018 Health care & life sciences investment outlook

Healthcare and life sciences will face continued disruption in 2018 as new technologies, economic pressures and consumer/patient demands change the industry.

Related content

KPMG Healthcare & Life Sciences Institute

Register to receive timely insights

Register to receive timely insights

About Healthcare & Life Sciences at KPMG

Our practice

Our capabilities

Meet our team